Table 2.

SSRDs in ASD—summary table.

Reference	Sample	Methods	Results
Asztely et al. (2019) [39]	N = 77 (F = 77; mean age: 27.2 ± 4.2)	SF-36	76% of the subjects reported chronic pain and a low quality of life
Zdankiewicz-Cigaa et al. (2021) [40]	ASD: N = 79 (F = 57; M = 22; mean age: 35.12 ± 6.32) HC: N = 126 (F = 99; M = 27; mean age: 34.77 ± 9.54)	TAS-20; AQ; BPQ-SF; DERS; SDQ-20	People with ASD scored higher on the AQ TAS-20, BPQ-SF autonomic reactivity subscale, SDQ-20, and DERS
Larkin et al. (2023) [41]	N = 202 (F = 146; M = 48; other = 8; mean age = 31.33 ± 12.90) ASD: N = 51 (F = 29; M = 17; mean age: 33.9 ± 13.5) self-suspected ASD: N = 32 (F = 19; M = 10; mean age: 36.1 ± 13.5) without ASD: N = 119 (F = 98; M = 21; mean age: 28.9 ± 12.0)	PHQ15; AQ-10; TAS-20; BAQ; IUS-12	Subjects with ASD showed more somatic symptoms than the non-ASD group; the self-suspected ASD group showed intermediate levels of symptoms; and the self-suspected ASD group showed significantly lower levels of interoception than the ASD group
Williams et al. (2019) [42]	ASD: N = 290 (F = 177; M = 113; mean age: 23.10 ± 2.38)	PHQ15; SRS-II; GAD-7; BDI-II; WHOQOL-4	Significantly higher levels of somatic symptoms in the ASD group, with most common symptoms being exhaustion, sleep issues, and menstruation issues